Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results

Last Modified: 2/1/1900


1.		Phase II Study of IFN-A-Enhanced, Single-Dose 131I-MOAB CC49 for Metastatic Hormone-Resistant Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				UAC-2153 NCI-B93-0013, B93-0013

Last Modified: 6/1/1995


2.		Phase II Study of 131I-Labeled MOAB CC-49 Plus IFN-G for Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MSKCC-93076A1 NCI-T94-0042C, T94-0042

Last Modified: 1/1/1992


3.		Phase II Study of 131I-Labeled MOAB CC-49 in Patients with Advanced Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MDA-ID-91022 NCI-T91-0216C, T91-0216

Last Modified: 11/1/1992


4.		Phase II Study of 131I-Labeled Anti-TAG-72 MOAB CC-49 in Patients with Hormone-Resistant Metastatic Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				UAC-2112 NCI-T91-0218C, T91-0218

Last Modified: 3/1/1993


5.		Phase II Study of 131I-Labeled Anti-TAG-72 Monoclonal Antibody (MOAB CC-49) Enhanced with IFN-A in Patients with Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				UAC-2131 NCI-T92-0169C, T92-0169

Last Modified: 5/1/1994


6.		Phase II Study of IFN-A Enhanced 131I-Labeled MOAB CC-49 and MOAB COL-1 in Patients with Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over								UAC-2152 NCI-B93-0012, B93-0012

Last Modified: 5/1/1999


7.		Phase I Study of 131I-Labeled Monoclonal Antibody CC-49 Followed by Total-Body Irradiation and Thiotepa with Autologous Peripheral Blood Stem Cell Rescue for Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 to physiologic 65				NCI				UAB-9505 NCI-B95-0005, B95-0005

Last Modified: 6/1/1992


8.		Phase I Study of 131I-Radiolabeled MOAB CC-49 in Patients with Metastatic or Unresectable Gastrointestinal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				19 to 65				NCI				UNMC-28191 NCI-T91-0159O, T91-0159

Last Modified: 10/10/2007


9.		Phase I Pilot Study of Intravenous 131I-CC49 Monoclonal Antibody with Deoxyspergualin Immunomodulation in Patients with Advanced Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over								MSKCC-93029 NCI-B92-0002, B92-0002

Last Modified: 2/1/1998


10.		Phase I Study of 131I-Labeled MOAB CC49 and Total Body Irradiation with Autologous Stem Cell Rescue Following Induction With High-Dose CTX for Hormone-Resistant Metastatic Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 to physiologic 60				NCI				UAC-1151 NCI-B93-0011, B93-0011

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute